Nektar Therapeutics
NASDAQ:NKTR 1:15:35 PM EDT
| Market Cap (Intraday) | 530.05M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $3.23 |
| 50-Day MA | $3.48 |
| 200-Day MA | $4.65 |
Nektar Therapeutics Stock, NASDAQ:NKTR
455 Mission Bay Boulevard South, San Francisco, California 94158
United States of America
Phone: +1.415.482.5300
Number of Employees: 740
Description
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.